Literature DB >> 26887762

Clinical Abacavir Hypersensitivity Reaction among Children in India.

Jaya Chakravarty1, Saurabh Sharma2, Anuradha Johri2, Ankita Chourasia2, Shyam Sundar2.   

Abstract

Abacavir is currently recommended as a part of first line regimen by National AIDS Control Organization. The objective of this study was to observe the incidence of clinically diagnosed abacavir Hypersensitivity reaction (HSR) among children on abacavir based therapy in the National program. In this observational study, all children started on abacavir were included and HSR reaction was diagnosed clinically as per National guidelines. HLA- B*5701 testing was done in children diagnosed with clinical abacavir HSR. Among 101 children started on abacavir during the study period, 8 [7.9 % (95 % CI 3.5-15.0 %)] children developed clinically diagnosed abacavir HSR. All children with concomitant illness (4/8) were HLA-B*5701 negative. Only 2 (25 %, 2/8) carried HLA-B*5701 allele. Fever with abdominal symptoms as compared to respiratory symptoms were more common in HLA-B*5701 positive cases. Overdiagnosis of clinically diagnosed abacavir HSR is common and could be decreased by treating concomitant illness before starting abacavir.

Entities:  

Keywords:  Abacavir; Antiretroviral therapy; HIV; HLA-B*5701; Hypersensitivity reaction

Mesh:

Substances:

Year:  2016        PMID: 26887762     DOI: 10.1007/s12098-016-2044-z

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  5 in total

1.  Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?

Authors:  Elizabeth J Phillips
Journal:  Clin Infect Dis       Date:  2006-05-26       Impact factor: 9.079

2.  Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

Authors:  S Mallal; D Nolan; C Witt; G Masel; A M Martin; C Moore; D Sayer; A Castley; C Mamotte; D Maxwell; I James; F T Christiansen
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

3.  [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].

Authors:  Noemí Pérez Prior; Amparo Rocher Milla; Enrique Soler Company; Juan Flores Cid; Benjamín Sarria Chust
Journal:  Farm Hosp       Date:  2009 May-Jun

4.  Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

Authors:  Arlene R Hughes; Michael Mosteller; Aruna T Bansal; Kirstie Davies; Stephen A Haneline; Eric H Lai; Keith Nangle; Trevor Scott; William R Spreen; Liling L Warren; Allen D Roses
Journal:  Pharmacogenomics       Date:  2004-03       Impact factor: 2.533

5.  HLA-B*5701 screening for hypersensitivity to abacavir.

Authors:  Simon Mallal; Elizabeth Phillips; Giampiero Carosi; Jean-Michel Molina; Cassy Workman; Janez Tomazic; Eva Jägel-Guedes; Sorin Rugina; Oleg Kozyrev; Juan Flores Cid; Phillip Hay; David Nolan; Sara Hughes; Arlene Hughes; Susanna Ryan; Nicholas Fitch; Daren Thorborn; Alastair Benbow
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

  5 in total
  3 in total

1.  Novel Concepts for Drug Hypersensitivity Based on the Use of Long-Time Scale Molecular Dynamic Simulation.

Authors:  Takahiro Murai; Norihito Kawashita; Yu-Shi Tian; Tatsuya Takagi
Journal:  J Pharm (Cairo)       Date:  2016-11-23

2.  Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.

Authors:  Julie Jesson; Laura Saint-Lary; Marc Harris Dassi Tchoupa Revegue; John O'Rourke; Claire L Townsend; Françoise Renaud; Martina Penazzato; Valériane Leroy
Journal:  Lancet Child Adolesc Health       Date:  2022-09-02

Review 3.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.